By Mike Miligi, Certified Medicare Insurance Planner- Michael M Insurance Services
A temporary CMS program is letting eligible Medicare beneficiaries access certain weight-loss GLP-1 medications for a flat $50 a month. Here’s exactly how it works, who qualifies, and how long it’s actually set to last.
Under federal law, Medicare Part D has never been allowed to cover medications prescribed purely for weight loss. That’s a real gap for the millions of Medicare beneficiaries living with obesity, especially as GLP-1 medications have become one of the most talked-about tools in medicine. In July 2026, CMS opened a narrow, temporary workaround: the Medicare GLP-1 Bridge Program. It’s not a permanent benefit, and it doesn’t cover every GLP-1 on the market — but for people who qualify, it can mean the difference between paying full retail price and paying $50 a month.
$50
Flat copay per 28–30 day supply for eligible drugs under the Bridge program — the same for everyone, regardless of income.
Jul 1, 2026
The date the Medicare GLP-1 Bridge officially went live nationwide.
Dec 31, 2027
The program’s current end date — extended from its original December 2026 sunset.
The Bridge was originally scheduled to run only through the end of 2026, until a permanent replacement (the BALANCE Model) was set to take over. CMS delayed that replacement indefinitely and extended the Bridge through December 31, 2027 instead — see “What Happens After 2027?” below.
The Medicare GLP-1 Bridge is a short-term demonstration program run directly by CMS — not by your individual Part D plan. Its purpose is narrow but significant: it gives eligible beneficiaries access to specific GLP-1 medications when prescribed for weight management, something standard Part D coverage is legally barred from paying for.
The program exists because CMS had originally planned a more permanent policy — the BALANCE Model — to take over GLP-1 weight-loss coverage starting in 2027. That rollout has since been delayed indefinitely, leaving a gap that the Bridge was extended to fill. In the meantime, CMS is also using the Bridge to collect real-world data on how beneficiaries use these medications, which will likely shape whatever permanent policy eventually replaces it.
This is the detail that surprises people most: the Bridge doesn’t work through your Part D plan’s normal formulary, deductible, or payment process. CMS uses a single central processor nationwide to handle prior authorization, claims, and pharmacy payment. Your Part D plan doesn’t have to opt in, and it has no say in whether you’re approved — it’s entirely a CMS-run process layered on top of your existing coverage.
This is the most common point of confusion. The Bridge covers only three specific products, and only when prescribed for weight management:
The single-dose vial and single-dose pen versions of Zepbound are not included — only the KwikPen. And this matters: if one of the excluded drugs is prescribed for an approved medical reason such as type 2 diabetes, it’s still covered the normal way, through your Part D plan’s standard formulary and cost-sharing. It simply isn’t part of this particular program.
You generally need a BMI of 35 or higher, or a BMI of 30 or higher along with at least one weight-related condition such as uncontrolled high blood pressure or heart failure with preserved ejection fraction (sometimes called diastolic heart failure).
You need to be enrolled in a standalone Part D plan or a Medicare Advantage plan that includes drug coverage (HMO, HMOPOS, or local/regional PPO with drug coverage). Special Needs Plans, employer group plans, and the Limited Income Newly Eligible Transition program are also eligible. Private fee-for-service plans, cost plans, and PACE are generally not eligible unless paired with a qualifying standalone drug plan. Dual-eligible beneficiaries (Medicare and Medicaid) can participate as long as their plan type qualifies.
If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH (formerly known as NASH) with moderate-to-advanced liver scarring, you’re not eligible for the Bridge — even if your current plan doesn’t happen to cover a GLP-1 for that condition. The reasoning is that these conditions already have an approved pathway to GLP-1 coverage through standard Part D, so the Bridge is reserved for people who don’t otherwise qualify for coverage.
If you’re approved, you pay a flat $50 for a 28- or 30-day supply — the same amount no matter your income or plan. A few important details most people miss:
The process is a little different from a typical prior authorization, and it starts with your doctor, not a form you fill out yourself:
This is the honest answer: nobody knows yet, and that’s worth sitting with rather than glossing over. The Bridge was designed from the start as temporary. It was originally supposed to hand off to the BALANCE Model in 2027, but that transition has been delayed indefinitely, which is the entire reason the Bridge got extended through the end of 2027 in the first place. There’s no guarantee a permanent replacement will be in place when the Bridge ends, and no guarantee the Bridge itself gets extended again. If you’re eligible now, that’s a reason to seriously consider using this window rather than waiting — not because of pressure, but because the terms available today aren’t promised to still be there in a couple of years.
It’s a temporary CMS program that lets eligible Medicare beneficiaries get certain GLP-1 medications for weight management at a flat $50 monthly copay, running outside your normal Part D coverage.
It started July 1, 2026, and currently runs through December 31, 2027. It was originally set to end in 2026, but was extended when its planned permanent replacement was delayed.
Only three: Foundayo® (the oral pill), Wegovy® (injection and tablet), and the Zepbound® KwikPen specifically. Other formulations and other GLP-1 drugs are not included.
No. Ozempic, Mounjaro, Rybelsus, Trulicity, Saxenda, and Victoza are not part of the Bridge program. If prescribed for an approved condition like type 2 diabetes, they may still be covered through your standard Part D plan.
A flat $50 for a 28- or 30-day supply, regardless of your income or which Part D plan you have.
No. The Bridge operates entirely outside your regular Part D benefit, so the $50 doesn’t apply toward your deductible, your coverage stage, or your annual out-of-pocket maximum.
You need a standalone Part D plan or a Medicare Advantage plan with drug coverage. Your specific plan doesn’t need to “opt in” — the Bridge works the same regardless of which qualifying plan you have.
Generally, a BMI of 35 or higher, or a BMI of 30 or higher with a qualifying condition such as uncontrolled high blood pressure or heart failure with preserved ejection fraction.
If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or advanced MASH, you’re excluded from the Bridge specifically — because those conditions already have an approved path to GLP-1 coverage through standard Part D.
It’s genuinely uncertain. The program’s planned permanent replacement has been delayed indefinitely, and there’s no guarantee of what coverage will look like once the Bridge’s current end date arrives.
